The M1, a lower-throughput version of the company's Aries System, can process up to six samples and six assays at a time.
Luminex expects Nanosphere to contribute between $13 million and $16 million to its consolidated revenue in 2016.
Luminex's anticipated FY 2016 revenue growth of 6 percent to 9 percent could potentially push higher into the double digits following the integration of Nanosphere.
The CE marking follows the approval of the Aries sample-to-answer system and HSV assay in Europe earlier this year and in the US in late 2015.
The company raised its offer to $1.70 per share from its previous agreement of $1.35 per share in response to an unsolicited bid from a third party.
Luminex said it will pay $1.35 per share for the molecular diagnostics developer, which today reported Q1 revenues rose 43 percent year over year.
The company reported record assay and royalty revenues, and said that system revenues grew 39 percent year over year.
The software connects Luminex's FDA-cleared Aries PCR-based platform with its multiplex xMap technology-based Magpix system.
Both the system, which detects and amplifies nucleic acids, and the assay, which identifies and types HSV DNA, were approved in the US late last year.
The investment bank set a 12-month price target of $2 for the company, saying its Verigene system and tests differentiate it from the competition.
A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.
NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.
The New York Times reports on how environmental DNA sampling could monitor endangered species.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.